0
Login

Novocure Ltd

instructor-image Bradford Hall

0

... En
... Certificate Company
... 0 Investors
... 00h 00m
NVCR logo
Novocure Ltd
NVCR Health Care
$17.07 ▼ -5.11%
$0.92 today · as of 06 Jun 2026
49 S.I.F.T
S.I.F.T.™ Analysis
Red
Login to Issue Journal
Caution – significant pillar weakness detected.
Last updated: 06 Jun 2026 · Confidence: 55%
Pillar Breakdown
🛡 Safety 35
Balance sheet or moat concerns are weighing on the score.
💰 Income 35
High cyclicality and lack of recurring revenue are limiting stability.
📊 Fundamentals 35
Strong growth but valuation is elevated.
⏱ Time 75
Shorter track record or weaker tailwinds.
🧠 Munger Reality Filter AVOID

Weak moat; negative profitability and unsustainable leverage indicate limited competitive durability despite sector presence.

Strengths: Longer time-in-market score of 75 shows some operating history, Healthcare sector exposure may offer niche technology angle
Risks: Deeply negative ROE of -39.4% signals ongoing losses, Debt-to-CFO ratio of 999 reflects severe cash-flow strain, Zero warchest and dividend yield leave no financial buffer
📈 Price History

Business Overview

Key Metrics
ROE (10yr)
-39.4%
Debt / CFO
N/A
Div. Yield
0.00%
FCF Growth
0.0%

FAQ

Financial Details

Recent Quarters
Quarter Revenue Gross Profit EPS
No quarterly data available.
Segment Breakdown
Data Center 56%
Client 28%
Gaming 9%
Embedded 7%

Management

Leadership Summary
  • Experienced team with long tenure in oncology device commercialization
  • Focus on scaling TTFields therapy across multiple cancer indications
  • Strong emphasis on R&D investment and geographic expansion
  • Transparent communication with investors on clinical and financial milestones
Track Record

Led multiple FDA approvals, achieved consistent revenue growth from under $100M to over $500M annually, and expanded commercial presence to more than 20 countries.

Recent Commentary

“Management highlighted accelerating adoption in glioblastoma and ovarian cancer trials during Q2 2024 earnings, while noting ongoing reimbursement progress in key markets.”

Analyst Reviews & Risks

Wall Street Consensus
4.6
out of 5 (Strong Buy)
Average Target: $485.00
Key Investment Risks
  • Deeply negative ROE of -39.4% signals ongoing losses
  • Debt-to-CFO ratio of 999 reflects severe cash-flow strain
  • Zero warchest and dividend yield leave no financial buffer
Ownership & Sentiment

Institutional Ownership: N/A%

Short Interest: N/A%

AI Investment Thesis
  • Novocure's TTFields therapy provides a novel, non-invasive modality with proven survival benefits in glioblastoma and mesothelioma.
  • Large addressable markets via pipeline expansion into NSCLC, ovarian, and pancreatic cancers with multiple Phase 3 readouts ahead.
  • Strong IP moat, growing reimbursement coverage, and high gross margins support scalable, high-margin revenue growth.
  • Increasing real-world adoption and KOL support position the company for durable market penetration in solid tumors.
  • Potential for strategic partnerships or M&A to accelerate global commercialization and de-risk late-stage development.
Key Catalysts & Risks
Catalysts
  • Positive LUNAR or INNOVATE-3 Phase 3 data readouts
  • FDA or CE mark approvals in new indications
  • Accelerated revenue growth and raised guidance
  • New reimbursement wins or guideline inclusions
Risks
  • Clinical trial failures or delays in key studies
  • Reimbursement hurdles or pricing pressure
  • Competition from targeted therapies and IO agents
  • Prolonged cash burn and dilution risk
Peer Comparison
Company P/E Rev Growth Gross Margin ROE Debt/Equity
NVDA N/A N/A% N/A% 61.51% 0.51
INTC N/A N/A% N/A% -1.64% 8.05
AVGO N/A N/A% N/A% 14.7% 3.03
AMD N/A N/A% N/A% 8.08% 999
  • ...

    Investors

     0

  • Ticker

     NVCR
  • ...

    Sector

     Health Care

  • Current Price

     $17.07

  • S.I.F.T. Score

     49
Login to Add Portfolio